LIK066 + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus (T2DM)
Conditions
Type 2 Diabetes Mellitus (T2DM)
Trial Timeline
Jun 1, 2011 → Feb 1, 2013
NCT ID
NCT01407003About LIK066 + Placebo
LIK066 + Placebo is a phase 1/2 stage product being developed by Novartis for Type 2 Diabetes Mellitus (T2DM). The current trial status is completed. This product is registered under clinical trial identifier NCT01407003. Target conditions include Type 2 Diabetes Mellitus (T2DM).
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03320941 | Phase 2 | Completed |
| NCT03205150 | Phase 2 | Completed |
| NCT03152591 | Phase 2 | Completed |
| NCT03100058 | Phase 2 | Completed |
| NCT02470403 | Phase 2 | Completed |
| NCT01915849 | Phase 1/2 | Completed |
| NCT01407003 | Phase 1/2 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus (T2DM)